Tegaserod

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Tegaserod 

Tegaserod 是一种血清素受体 4 激动剂 (HTR4),用于治疗肠易激综合征 (IBS)。具有抗肿瘤活性。

Tegaserod

Tegaserod Chemical Structure

CAS No. : 145158-71-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Tegaserod 的其他形式现货产品:

Tegaserod maleate

生物活性

Tegaserod is a serotonin receptor 4 agonist (HTR4) used in the treatment of irritable bowel syndrome (IBS). Anti-tumor activity[1].

IC50 & Target

5-HT4 Receptor

 

体外研究
(In Vitro)

Tegaserod (1.5 and 3 μM) induces apoptosis in the B16F10 murine melanoma cell line as well as several human melanoma cell lines[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: B16F10 cells
Concentration: 78 nM-10 μM
Incubation Time: 72 hours
Result: Had anti-cancer activity with IC50 values in the low micromolar range as assessed by MTT assay following 72 h of exposure.

体内研究
(In Vivo)

Tegaserod (5 mg/kg) delays tumor growth, reduces metastases, increases survival and suppresses p-S6 in vivo[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 J mice were subcutaneously injected with B16F10 cells[1]
Dosage: 5 mg/kg
Administration: Administered intraperitoneally (i.p.) daily for five consecutive days
Result: Treatment significantly decreased tumor growth and resulted in only slight decreases in weight following treatment.

分子量

301.39

Formula

C16H23N5O

CAS 号

145158-71-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Wei Liu, et al. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2020 Feb 21;39(1):38.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

发表回复